{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:57:32Z","timestamp":1786982252738,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Real-world evidence on locally advanced or metastatic urothelial carcinoma (la\/mUC) management in Spain is limited. This study describes patient characteristics, treatment patterns, survival, and health care resource utilization (HCRU) in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/patients<\/jats:title>\n                    <jats:p>This retrospective observational study included all adults with a first diagnosis\/record of la\/mUC (index date) from January 2015 to June 2020 at nine university hospitals in Spain. Data were collected up to December 31, 2020 (end of study), death, or loss to follow-up. Patient characteristics, treatment patterns, median overall survival (OS) and progression-free survival (PFS) from index date (Kaplan\u2013Meier estimates), and disease-specific HCRU were described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 829 patients, median age at diagnosis was 71\u00a0years; 70.2% had\u2009\u2265\u20091 comorbidity, and 52.5% were eligible for cisplatin. Median follow-up was 12.7\u00a0months. Most (84.7%) patients received first-line systemic treatment; of these, 46.9% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009329) received second-line and 16.6% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009116) received third-line therapy. Chemotherapy was the most common treatment in all lines of therapy, followed by programmed cell death protein 1\/ligand 1 inhibitors. Median (95% confidence interval) OS and PFS were 18.8 (17.5\u201321.5) and 9.9 (8.9\u201310.5) months, respectively. Most patients required\u2009\u2265\u20091 outpatient visit (71.8%), inpatient admission (56.6%), or emergency department visit (56.5%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Therapeutic patterns were consistent with Spanish guideline recommendations. Chemotherapy had a role in first-line treatment of la\/mUC in Spain during the study period. However, the disease burden remains high, and new first-line treatments recommended in the latest European guidelines should be made available to patients in Spain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-024-03734-8","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T07:02:59Z","timestamp":1728025379000},"page":"2232-2240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-1331","authenticated-orcid":false,"given":"Javier","family":"Puente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Mendez-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Garc\u00eda del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Luque-Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbano","family":"Anido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Strunz-McKendry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Ortiz Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Gonz\u00e1lez Portela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"3734_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"3734_CR2","unstructured":"Sociedad Espanola de Oncologia Medica. Las cifras del cancer en Espana 2023. 2023. https:\/\/seom.org\/images\/Las_cifras_del_Cancer_en_Espana_2023.pdf. Accessed March 28, 2023."},{"key":"3734_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.currproblcancer.2014.06.001","volume":"38","author":"JC Park","year":"2014","unstructured":"Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer. 2014;38:80\u2013108. https:\/\/doi.org\/10.1016\/j.currproblcancer.2014.06.001.","journal-title":"Curr Probl Cancer"},{"key":"3734_CR4","volume-title":"Bladder cancer","author":"H Kaseb","year":"2024","unstructured":"Kaseb H, Aeddula NR. Bladder cancer. StatPearls: StatPearls Publishing, Treasure Island; 2024."},{"key":"3734_CR5","unstructured":"Sociedad Espanola de Oncologia Medica. Las cifras del cancer en Espana 2022. 2022. https:\/\/seom.org\/images\/LAS_CIFRAS_DEL_CANCER_EN_ESPANA_2022.pdf. Accessed March 28, 2023."},{"key":"3734_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:244\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012.","journal-title":"Ann Oncol"},{"key":"3734_CR7","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/jco.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432\u20138. https:\/\/doi.org\/10.1200\/jco.2011.34.8433.","journal-title":"J Clin Oncol"},{"key":"3734_CR8","unstructured":"European Medicines Agency. Bavencio-H-C-004338-II-0018: EPAR - Assessment report - Variation [EMA\/CHMP\/3166\/2021]. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/bavencio-h-c-004338-ii-0018-epar-assessment-report-variation_en.pdf. Accessed July 20, 2022."},{"key":"3734_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, et al. ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.001.","journal-title":"Ann Oncol"},{"key":"3734_CR10","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1200\/JCO.2022.40.16_suppl.4577","volume":"40","author":"S Gupta","year":"2022","unstructured":"Gupta S, Bellmunt J, Plimack ER, et al. Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC). J Clin Oncol. 2022;40:4577. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4577.","journal-title":"J Clin Oncol"},{"key":"3734_CR11","unstructured":"European Medicines Agency. Padcev-H-C-005392\u20130000: EPAR - Assessment report [EMA\/249357\/2022]. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/padcev-epar-public-assessment-report_en.pdf. Accessed April 2, 2024."},{"key":"3734_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.juro.2013.08.049","volume":"191","author":"B Mi\u00f1ana","year":"2014","unstructured":"Mi\u00f1ana B, C\u00f3zar JM, Palou J, et al. Bladder cancer in Spain 2011: population based study. J Urol. 2014;191:323\u20138. https:\/\/doi.org\/10.1016\/j.juro.2013.08.049.","journal-title":"J Urol"},{"key":"3734_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8:15. https:\/\/doi.org\/10.3390\/medsci8010015.","journal-title":"Med Sci (Basel)"},{"key":"3734_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.09.010","author":"N Milloy","year":"2023","unstructured":"Milloy N, Kirker M, Unsworth M, et al. Real-world analysis of treatment patterns and platinum-based treatment eligibility of patients with metastatic urothelial cancer in 5 European countries. Clin Genitourin Cancer. 2023. https:\/\/doi.org\/10.1016\/j.clgc.2023.09.010.","journal-title":"Clin Genitourin Cancer"},{"key":"3734_CR15","doi-asserted-by":"publisher","first-page":"195.e1","DOI":"10.1016\/j.urolonc.2021.11.014","volume":"40","author":"DM Geynisman","year":"2022","unstructured":"Geynisman DM, Broughton E, Hao Y, Zhang Y, Le T, Huo S. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States. Urol Oncol. 2022;40:195.e1-e11. https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.014.","journal-title":"Urol Oncol."},{"key":"3734_CR16","doi-asserted-by":"publisher","first-page":"e637","DOI":"10.1016\/j.clgc.2017.12.009","volume":"16","author":"SM Yip","year":"2018","unstructured":"Yip SM, Kaiser J, Li H, North S, Heng DYC, Alimohamed NS. Real-world outcomes in advanced urothelial cancer and the role of neutrophil to lymphocyte ratio. Clin Genitourin Cancer. 2018;16:e637\u201344. https:\/\/doi.org\/10.1016\/j.clgc.2017.12.009.","journal-title":"Clin Genitourin Cancer"},{"key":"3734_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100266","volume":"25","author":"A Richters","year":"2020","unstructured":"Richters A, Mehra N, Meijer RP, et al. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study. Cancer Treat Res Commun. 2020;25: 100266. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100266.","journal-title":"Cancer Treat Res Commun"},{"issue":"16 suppl","key":"3734_CR18","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1200\/JCO.2022.40.16_suppl.4565","volume":"40","author":"GP Sonpavde","year":"2022","unstructured":"Sonpavde GP, Galsky MD, Wright P, et al. Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma [abstract]. J Clin Oncol. 2022;40(16 suppl):4565. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4565.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03734-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03734-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03734-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T02:03:46Z","timestamp":1745633026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03734-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["3734"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03734-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Javier Puente reports consulting fees from Pfizer and Roche; payment or honoraria from Astra Zeneca, Eisai, Janssen, MSD, Pfizer, BMS, and Merck; Participation on a Data Safety Monitoring Board or Advisory Board at Astra Zeneca, Janssen, MSD, Pfizer, BMS, and Merck. Alvaro Pinto reports payment or honoraria from Janssen, Astellas, Pfizer, BMS, MSD, Bayer, Ipsen, Astra Zeneca, Roche, and Merck; support for attending meetings and\/or travel from MSD, Ipsen, Janssen, Pfizer, BMS. Maria Jos\u00e9 Mendez-Vidal has received travel grants from Astellas, BMS, Roche, Pfizer, Merck, and Ipsen and honoraria for speaker engagements, advisory boards and continuous medical education from, Astellas, Sanofi, Bayer, Roche, Ipsen, BMS, MSD, Pfizer, Eusa Pharma, Eisai, Novartis, AAA and AstraZeneca. Xavier Garc\u00eda del Muro reports consulting fees from Pfizer, Merck, Roche, Lilly, Ipsen, BMS, Eisai, GSK, EusaPharma, and Deciphera; payment or honoraria from Pfizer, Eisai, and Astellas Pharma; support for attending meetings and\/or travel from Pfizer and Merck. Pablo Maroto has nothing to report. Sergio Vazquez has nothing to report. Raquel Luque-Caro has nothing to report. Urbano Anido reports travel grants from Ipsen, Bayer, Merck-Pfizer; advisory boards Advanced Accelerator Applications, Ipsen, Astra-Zeneca, Merck, Pfizer, Astellas, Bayer; honoraria for speaker engagements and continuous medical education from Advanced Accelerator Applications, Ipsen, Astra-Zeneca, Merck, Eisai, BMS, Kyowa Kirin, Rovi. Torsten Strunz-McKendry is an employee of Astellas Pharma, Inc. Anil Upadhyay is an employee of Astellas Pharma, Inc. Jose Montes has nothing to report. Aurora Ortiz Nu\u00f1ez is an employee of Astellas Pharma, Inc. Judit Gonz\u00e1lez Portela is an employee of Astellas Pharma, Inc. Daniel Castellano reports payment or honoraria from Pfizer, AstraZeneca, BMS, Roche, Novartis, MSD, Merck, Astellas, Janssen, Bayer, Exelisis, Ipsen, Seagen, Gilead, Genetech; and support for attending meetings and\/or travel from Pfizer, AstraZeneca, Roche, Novartis, Merck, Janssen, Bayer, Exelisis, Ipsen, Genetech.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"An independent ethics committee reviewed and approved the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Given the retrospective nature of the study, informed consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}